This stock is no longer traded. It was delisted on July 2, 2026. Prices stop on that date; discussion is still counted.
Generated by AI
Finch Therapeutics Group Inc. is an innovative biotech company focused on developing microbiome-based therapeutics. The company's primary function is to leverage the human microbiome to create treatments for a range of conditions, particularly those involving the gastrointestinal system. By utilizing a rich resource of biological and clinical data, Finch Therapeutics strives to address unmet medical needs through its advanced therapeutic approaches. This includes the development of next-generation therapies that aim to restore a healthy microbiome balance in patients. Finch Therapeutics plays a significant role in the biopharmaceutical industry by pioneering approaches that can potentially transform how microbial therapies are developed and administered. The company's focus includes advancing its pipeline through clinical trials, potentially impacting the future treatment paradigms in medicine. As part of the burgeoning field of microbiome research, Finch Therapeutics represents innovation in a sector increasingly recognized for its relevance to human health and disease.
Website75 State Street
Boston, MA, 02109
United States
Summary of Aug 12's posts. Generated by AI.
Summary of Apr 23's posts. Generated by AI.
Summary of Jun 12's posts. Generated by AI.
Investors talking about FNCH also mention these. Each card shows that asset’s own numbers for the past 24 hours.